Sign inJoin waitlistJoin the waitlist

DL

David Liebner

Section Chief, Sarcoma · Ohio State University Hospital

Credentials: · · ·

History

Sarcoma Section · Ohio State University Hospital
Present

Medical Oncology
2010–2012
Internal Medicine
University at Buffalo School of Medicine
2007–2010
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
2003–2007

Research

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 336 citations
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
The Lancet · 2024 · 258 citations
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
Journal of the National Comprehensive Cancer Network · 2020 · 239 citations

James Chen
15 papers
Raphael Pollock
8 papers
Hans Iwenofu
6 papers
Kristen Ganjoo
6 papers
SS
Scott Schuetze
6 papers
Valerie Grignol
6 papers
Christian Meyer
5 papers
Edwin Choy
5 papers
Martin McCarter
5 papers
Richard Riedel
5 papers
Vicki Keedy
5 papers
Alberto Pappo
4 papers

Clinical trials

Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
Principal investigator · Not yet recruiting · Phase 3
Ohio State University Comprehensive Cancer Center
2026–2028
Niraparib for the Treatment of Leiomyosarcoma
Principal investigator · Withdrawn · Phase 2
David Liebner, MD
2023–2025
An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry
Principal investigator · Recruiting
Ohio State University Comprehensive Cancer Center
2015–2027
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028